CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B
- 1st Edition, Volume 210 - January 22, 2025
- Editor: Vijai Singh
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 2 4 2 0 - 1
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 2 4 2 1 - 8
CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key te… Read more
CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR –Cas systems for metabolic disorders, Recent progress in CRISPR –Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR –Cas systems for cataract and blindness, Advances in CRISPR –Cas systems for muscular dystrophy, Recent development in CRISPR –Cas systems for cardiac disease, Current approaches in CRISPR –Cas systems for diabetes, and much more.
Additional sections cover Advances in CRISPR –Cas systems for liver disease, Advances in CRISPR –Cas systems for lung disease, Advances in CRISPR –Cas systems for kidney diseases, Current progress in CRISPR –Cas systems for rare disease, Advances in CRISPR –Cas systems for heredity disease, Recent progress in CRISPR –Cas systems for neurological disorders, and CRISPR challenges in clinical developments.
Additional sections cover Advances in CRISPR –Cas systems for liver disease, Advances in CRISPR –Cas systems for lung disease, Advances in CRISPR –Cas systems for kidney diseases, Current progress in CRISPR –Cas systems for rare disease, Advances in CRISPR –Cas systems for heredity disease, Recent progress in CRISPR –Cas systems for neurological disorders, and CRISPR challenges in clinical developments.
- Provides CRISPR-Cas systems for metabolic disorders, retinal disease cataracts, and blindness
- Offer updates on muscular dystrophy, cardiac disease, diabetes, and liver disease
- Includes content on lung disease, kidney diseases, rare diseases, heredity diseases, neurological disorders, and CRISPR challenges in clinical developments
Students, researchers, clinicians, entrepreneurs, and stakeholders
Preface
Vijai Singh
1. Current approaches in CRISPR –Cas systems for metabolic disorders
DHRUV KUMAR
2. Recent progress in CRISPR –Cas systems for CRISPR for retinal diseases
Mayank Bansal
3. Recent progress in CRISPR –Cas systems for cataract and blindness
Suresh Ramakrishna
4. Advances in CRISPR –Cas systems for muscular dystrophy
Vancha Harish
5. Recent development in CRISPR –Cas systems for cardiac disease
Xin Wang
6. Current approaches in CRISPR –Cas systems for diabetes
L. Karthik
7. Advances in CRISPR –Cas systems for liver disease
Majid Mojarrad
8. Advances in CRISPR –Cas systems for lung disease
Suresh Ramakrishna
9. Advances in CRISPR –Cas systems for kidney diseases
Anil Bhanudas Gaikwad
10. Current progress in CRISPR –Cas systems for rare disease
Ajay Kumar I
11. Advances in CRISPR –Cas systems for heredity disease
DHRUV KUMAR
12. Recent progress in CRISPR –Cas systems for neurological disorders
Anand Krishna Tiwari
13. CRISPR challenges in clinical developments
Hossein Soltaninejad, Mohadeseh Khoshandam and Saman Hosseinkhani
Vijai Singh
1. Current approaches in CRISPR –Cas systems for metabolic disorders
DHRUV KUMAR
2. Recent progress in CRISPR –Cas systems for CRISPR for retinal diseases
Mayank Bansal
3. Recent progress in CRISPR –Cas systems for cataract and blindness
Suresh Ramakrishna
4. Advances in CRISPR –Cas systems for muscular dystrophy
Vancha Harish
5. Recent development in CRISPR –Cas systems for cardiac disease
Xin Wang
6. Current approaches in CRISPR –Cas systems for diabetes
L. Karthik
7. Advances in CRISPR –Cas systems for liver disease
Majid Mojarrad
8. Advances in CRISPR –Cas systems for lung disease
Suresh Ramakrishna
9. Advances in CRISPR –Cas systems for kidney diseases
Anil Bhanudas Gaikwad
10. Current progress in CRISPR –Cas systems for rare disease
Ajay Kumar I
11. Advances in CRISPR –Cas systems for heredity disease
DHRUV KUMAR
12. Recent progress in CRISPR –Cas systems for neurological disorders
Anand Krishna Tiwari
13. CRISPR challenges in clinical developments
Hossein Soltaninejad, Mohadeseh Khoshandam and Saman Hosseinkhani
- Edition: 1
- Volume: 210
- Published: January 22, 2025
- Language: English
VS
Vijai Singh
Prof. Vijai Singh is currently serving as Head of the Department of Biosciences, School of Science and Dean (Research & Innovation) at Indrashil University, Rajpur, Mehsana, India. Prior to this, he held the position of Associate Professor in the same department at Indrashil University. He has also served as Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, and in the Department of Biotechnology at the Invertis University, Bareilly, India. Earlier of his career, Prof. Singh worked as a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and at the School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He earned his Ph.D. in Biotechnology in 2009 from the ICAR-National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India. His doctoral research focused on the development of molecular and immunoassays for the diagnosis of Aeromonas hydrophila. Prof. Singh’s research interests lies in the design and construction of novel biosynthetic pathways for production of medically and industrially important biomolecules. His laboratory is also actively engaged in developing CRISPR-Cas systems for gene knock out, knock in, gene regulation and diagnostic. With over 15 years of research and teaching experience, his areas of expertise include synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has an extensive academic record, with over 110 articles, 89 book chapters, 26 books and 3 patents to his credits. Prof. Singh has received number of prestigious awards, including the Bioclues Innovation, Research and Development Award (2023) from the BIOCLUES Society, the Vice Chancellor's Best Research Award (2023) from Indrashil University, and the Agathiyar Chemical Biology Award (2023) from the Society of Chemical and Synthetic Biology. At Indrashil University, he currently serves as chairman of the Board of Study, and is a member of the Academic Council of Indrashil University. He also holds the position of the Member Secretary of the Institutional Biosafety Committee (IBSC) at the university. Dr. Singh is actively involved in national and international scientific advisory roles.
Affiliations and expertise
Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, IndiaRead CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B on ScienceDirect